Use of psychotropic substances among elite athletes - a narrative review.


Journal

Swiss medical weekly
ISSN: 1424-3997
Titre abrégé: Swiss Med Wkly
Pays: Switzerland
ID NLM: 100970884

Informations de publication

Date de publication:
15 02 2021
Historique:
entrez: 27 2 2021
pubmed: 28 2 2021
medline: 21 10 2021
Statut: epublish

Résumé

Elite athletes may use psychotropic substances for recreational reasons, (perceived) performance enhancement or self-medication. Causes can overlap. For athletes, substance use may be associated with various medical and social risks. Psychoactive substances include alcohol and nicotine, illicit and various prescription drugs, which all have a potential for abuse and dependence. This paper reviews the existing literature on the use of psychoactive substances and associated substance use disorders among elite athletes in terms of prevalence, patterns of use, as well as underlying causes and risk factors. Due to the heterogeneous and partially fragmentary study data, a narrative approach with selection of applicable publications of a Medline search was chosen. The most commonly used psychoactive substances among elite athletes were alcohol, nicotine, cannabis, stimulants and (prescription) opioids. Overall consumption rates are lower in professional sports than in the general population, but use of several substances (smokeless tobacco products, prescription opioids, stimulants) have high prevalence in specific sports and athlete groups. Substance use is subject to multiple risk factors and varies by substance class, sport discipline, country and gender, among other factors. Knowledge on the underlying causes and patterns of substance use, as well as the prevalence of substance use disorders in professional sports, is still limited. High prevalence of various substances (i.e., nicotine, prescription opioids) may indicate potentially harmful patterns of use, requiring further research. Specific preventive and therapeutic concepts for the treatment of substance use disorders in elite athletes should be developed.

Sections du résumé

BACKGROUND AND AIMS
Elite athletes may use psychotropic substances for recreational reasons, (perceived) performance enhancement or self-medication. Causes can overlap. For athletes, substance use may be associated with various medical and social risks. Psychoactive substances include alcohol and nicotine, illicit and various prescription drugs, which all have a potential for abuse and dependence. This paper reviews the existing literature on the use of psychoactive substances and associated substance use disorders among elite athletes in terms of prevalence, patterns of use, as well as underlying causes and risk factors.
METHODS
Due to the heterogeneous and partially fragmentary study data, a narrative approach with selection of applicable publications of a Medline search was chosen.
RESULTS
The most commonly used psychoactive substances among elite athletes were alcohol, nicotine, cannabis, stimulants and (prescription) opioids. Overall consumption rates are lower in professional sports than in the general population, but use of several substances (smokeless tobacco products, prescription opioids, stimulants) have high prevalence in specific sports and athlete groups. Substance use is subject to multiple risk factors and varies by substance class, sport discipline, country and gender, among other factors.
CONCLUSION
Knowledge on the underlying causes and patterns of substance use, as well as the prevalence of substance use disorders in professional sports, is still limited. High prevalence of various substances (i.e., nicotine, prescription opioids) may indicate potentially harmful patterns of use, requiring further research. Specific preventive and therapeutic concepts for the treatment of substance use disorders in elite athletes should be developed.

Identifiants

pubmed: 33638352
doi: 10.4414/smw.2021.20412
pii: Swiss Med Wkly. 2021;151:w20412
doi:
pii:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

w20412

Auteurs

Jan Exner (J)

Klinik für Psychiatrie, Psychotherapie und Psychosomatik, Psychiatrische Klinik der Universität Zürich, Switzerland.

Raoul Bitar (R)

Klinik für Psychiatrie, Psychotherapie und Psychosomatik, Psychiatrische Klinik der Universität Zürich, Switzerland.

Xaver Berg (X)

Klinik für Psychiatrie, Psychotherapie und Psychosomatik, Psychiatrische Klinik der Universität Zürich, Switzerland.

Eva-Maria Pichler (EM)

Department of Psychiatry and Psychotherapy, Psychiatric Services Aargau AG, Brugg-Windisch, Switzerland.

Marcus Herdener (M)

Klinik für Psychiatrie, Psychotherapie und Psychosomatik, Psychiatrische Klinik der Universität Zürich, Switzerland.

Erich Seifritz (E)

Klinik für Psychiatrie, Psychotherapie und Psychosomatik, Psychiatrische Klinik der Universität Zürich, Switzerland.

Malte Christian Claussen (MC)

Klinik für Psychiatrie, Psychotherapie und Psychosomatik, Psychiatrische Klinik der Universität Zürich, Switzerland / Private Clinic Wyss AG, Munchenbuchsee, Switzerland / Psychiatric Services Grisons, Chur, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH